Recce Pharmaceuticals - R327 continues to progress in clinical trials
Recce Pharmaceuticals raised A$11.0m (gross) in September and October. Most of the proceeds (A$6m) will be directed towards the company’s clinical...
245 Views
Recce Pharmaceuticals - R327 progressing in rapid infusion study
Recce recently reported the completion of its data review from its earlier long-infusion Phase I study of the intravenous (IV) RECCE 327 (R327)...
301 Views
Recce Pharmaceuticals - Gearing up for more R327 studies
Recent months have been eventful for Recce Pharmaceuticals, with the company presenting its Q323 operational update and announcing ethics approval...
155 Views
Recce Pharmaceuticals - Seeking a breakthrough in sepsis
Recce Pharmaceuticals is developing a novel class of broad-spectrum synthetic anti-infective drugs to which, so far, all tested bacteria have been...
235 Views